Velez et al's recent case report [1] , describing the efficacy of fomepizole as the sole antidotal therapy for ethylene glycol toxicity, is pertinent to the practice of medical toxicology as there is now a mounting body of evidence highlighting the value of this treatment approach. Hemodialysis is not a benign procedure; hypotension, the most worrisome acute complication, is cited to occur in 25-55% of treatments [2] . Furthermore, the overall costeffectiveness must be considered when taking into account resource utilization. In a case report by Boyer et al [3] , the cost of using fomepizole as a single therapy was compared against that of hemodialysis, with a 65% increased cost associated with the latter modality. When hemodialysis is used as the primary therapy, these patients concomitantly receive fomepizole at fourhour dosing intervals instead of every twelve hours; the antidote itself is also eliminated by dialysis, further increasing the financial burden.
